Should I buy or sell Reviva Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks .

What is Reviva Pharmaceuticals' stock price target for 2024?

4 equities research analysts have issued 1 year price objectives for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they predict the company's share price to reach $16.75 in the next twelve months. This suggests a possible upside of 280.7% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts .

How have RVPH shares performed in 2024?

Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of 2024. Since then, RVPH stock has decreased by 14.6% and is now trading at $4.40. View the best growth stocks for 2024 here .

When is Reviva Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our RVPH earnings forecast .

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its earnings results on Tuesday, November, 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.09.

Who are Reviva Pharmaceuticals' major shareholders?

Reviva Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%) and Vontobel Holding Ltd. (0.06%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc. View institutional ownership trends .

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

$4.40

+0.07 (+1.62%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $4.25
▼
$4.48
50-Day Range: $3.56
▼
$5.52
52-Week Range: $3.50
▼
$9.25

Volume: 192,000 shs
Average Volume: 368,371 shs
Market Capitalization: $122.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.75

Get Reviva Pharmaceuticals alerts:

Reviva Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 280.7% Upside
$16.75 Price Target
Short Interest: Healthy
2.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.54) to ($0.92) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

379th out of 922 stocks

Pharmaceutical Preparations Industry

178th out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.75, Reviva Pharmaceuticals has a forecasted upside of 280.7% from its current price of $4.40.
Amount of Analyst Coverage
Reviva Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.62% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Reviva Pharmaceuticals has recently decreased by 20.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Reviva Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reviva Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RVPH.

2.7

News and Social Media Coverage

News Sentiment
Reviva Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 24.09% of the stock of Reviva Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($1.54) to ($0.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reviva Pharmaceuticals is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reviva Pharmaceuticals is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reviva Pharmaceuticals has a P/B Ratio of 7.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

RVPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVPH Stock News Headlines

January 25, 2024 | finance.yahoo.com

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

January 17, 2024 | ca.finance.yahoo.com

RVPH Jan 2025 7.500 call

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

January 10, 2024 | finanznachrichten.de

Reviva Pharmaceuticals: Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

January 10, 2024 | finance.yahoo.com

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

January 4, 2024 | finance.yahoo.com

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

December 28, 2023 | benzinga.com

Reviva Pharmaceuticals Stock (NASDAQ:RVPH) Dividends: History, Yield and Dates

December 26, 2023 | finance.yahoo.com

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

February 12, 2024 | The Freeport Society (Ad)

Biden Out, _______ In?

A new poll shows that two-thirds of Democrats want Biden to drop out of the 2024 race. The truth will shock you.

December 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Reviva Pharmaceuticals Holdings (RVPH) and Oculis Holding (OCS)

November 30, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

November 27, 2023 | msn.com

Reviva Pharmaceuticals Holdings (RVPH) Price Target Increased by 13.48% to 17.17

November 21, 2023 | finanznachrichten.de

Reviva Pharmaceuticals: Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 20, 2023 | finance.yahoo.com

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 20, 2023 | finance.yahoo.com

RVPH: Raise & RECOVER Results Review

November 16, 2023 | finance.yahoo.com

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 16, 2023 | finance.yahoo.com

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 15, 2023 | finanznachrichten.de

Reviva Pharmaceuticals: Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 14, 2023 | finance.yahoo.com

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 14, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Holdings Inc Reports Q3 2023 Financial Results

November 2, 2023 | msn.com

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

November 1, 2023 | morningstar.com

Reviva Pharmaceuticals Holdings Inc Ordinary Shares

November 1, 2023 | finance.yahoo.com

RVPH: RECOVER Topline

October 31, 2023 | msn.com

HC Wainwright & Co. Maintains Reviva Pharmaceuticals Holdings (RVPH) Buy Recommendation

October 31, 2023 | msn.com

Roth MKM Reiterates Reviva Pharmaceuticals Holdings (RVPH) Buy Recommendation

October 30, 2023 | reuters.com

REVIVA PHARMACEUTICALS, INC.

October 30, 2023 | benzinga.com

Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial

See More Headlines

Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 2/11/2024
Next Earnings (Estimated): 4/04/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RVPH
CUSIP: N/A
CIK: 1742927
Web: www.revivapharma.com
Phone: (408) 501-8881
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.75
High Stock Price Target: $20.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +280.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,344.46%
Return on Assets: -307.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.41
Quick Ratio: 0.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 7.33

Miscellaneous

Outstanding Shares: 27,920,000
Free Float: 19,032,000
Market Cap: $122.85 million
Optionable: Optionable
Beta: -0.01

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Laxminarayan Bhat Ph.D. (Age 59)
Founder, CEO, President & Director
Comp: $560k
Mr. Narayan Prabhu (Age 52)
Chief Financial Officer
Comp: $412.5k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RVPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings or view top-rated stocks.
What is Reviva Pharmaceuticals' stock price target for 2024?: 4 equities research analysts have issued 1 year price objectives for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they predict the company's share price to reach $16.75 in the next twelve months. This suggests a possible upside of 280.7% from the stock's current price.
View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts.
How have RVPH shares performed in 2024?: Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of 2024. Since then, RVPH stock has decreased by 14.6% and is now trading at $4.40.
View the best growth stocks for 2024 here.
When is Reviva Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our RVPH earnings forecast.

How were Reviva Pharmaceuticals' earnings last quarter?: Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its earnings results on Tuesday, November, 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.09.
Who are Reviva Pharmaceuticals' major shareholders?: Reviva Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%) and Vontobel Holding Ltd. (0.06%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc.
View institutional ownership trends.
How do I buy shares of Reviva Pharmaceuticals?: Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVPH) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial